Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress
JJ Cui - Journal of medicinal chemistry, 2014 - ACS Publications
The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological
functions including embryological development, wound healing, and tissue regeneration. …
functions including embryological development, wound healing, and tissue regeneration. …
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
K Liu, JJ Cui, Y Zhan, QY Ouyang, QS Lu, DH Yang… - Molecular Cancer, 2022 - Springer
The tumor microenvironment (TME) is essential for immune escape by tumor cells. It plays
essential roles in tumor development and metastasis. The clinical outcomes of tumors are …
essential roles in tumor development and metastasis. The clinical outcomes of tumors are …
Advanced space-based solar observatory (ASO-S): an overview
…, J Wu, L Deng, Y Huang, JF Yang, JJ Cui… - … in Astronomy and …, 2019 - iopscience.iop.org
The Advanced Space-based Solar Observatory (ASO-S) is a mission proposed for the 25th
solar maximum by the Chinese solar community. The scientific objectives are to study the …
solar maximum by the Chinese solar community. The scientific objectives are to study the …
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and …
JJ Cui, M Tran-Dubé, H Shen, M Nambu… - Journal of medicinal …, 2011 - ACS Publications
Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor
tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal …
tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal …
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
…, S Yamazaki, TB Koudriakova, G Alton, JJ Cui… - Cancer research, 2007 - AACR
The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have
been implicated in the progression of several human cancers and are attractive therapeutic …
been implicated in the progression of several human cancers and are attractive therapeutic …
A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo
…, R Blake, KE Lipson, J Ramphal, S Do, JJ Cui… - Cancer research, 2003 - AACR
The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have
been implicated in the development and progression of several human cancers and are …
been implicated in the development and progression of several human cancers and are …
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3 …
…, A Brooun, BJ Burke, MR Collins, JJ Cui… - Journal of medicinal …, 2014 - ACS Publications
Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive
non-small-cell lung carcinoma patients, progression during treatment eventually develops…
non-small-cell lung carcinoma patients, progression during treatment eventually develops…
Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations
…, S Stopatschinskaja, DM Hyman, RC Doebele, JJ Cui… - Cancer discovery, 2018 - AACR
… JJ Cui has ownership interest (including stock, patents, etc.) in TP Therapeutics, Inc. AT
Shaw is a consultant/advisory board member for member for TP Therapeutics, Pfizer, Blueprint …
Shaw is a consultant/advisory board member for member for TP Therapeutics, Pfizer, Blueprint …
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
…, FM Shao, K Wang, N Sheng, R Li, JJ Cui… - … and Targeted Therapy, 2021 - nature.com
Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase
(RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it …
(RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it …
Heterogeneity of proangiogenic features in mesenchymal stem cells derived from bone marrow, adipose tissue, umbilical cord, and placenta
Background Mesenchymal stem cells (MSCs) have been widely proven effective for therapeutic
angiogenesis in ischemia animal models as well as clinical vascular diseases. Because …
angiogenesis in ischemia animal models as well as clinical vascular diseases. Because …
